A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b [edoxaban] Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial).

Trial Profile

A Phase 3, Randomized, Double-Blind, Double-Dummy Efficacy and Safety Study of the Oral Factor Xa Inhibitor DU-176b [edoxaban] Compared With Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-5 Trial).

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2016

At a glance

  • Drugs Edoxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms STARS J-5; STARS J-V
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 28 Jul 2011 Pooled analysis published in the Journal of Thrombosis and Haemostasis.
    • 08 Dec 2010 Results were presented at the 52nd Annual Meeting of the American Society of Hematology, according to a Daiichi Sankyo Company media release
    • 02 Sep 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top